The Jackson Laboratory

The Mouseion at the JAXlibrary
Faculty Research 2022

Faculty Research

7-5-2022

Programmable RNA-Guided Large DNA Transgenesis by CRISPR/
Cas9 and Site-Specific Integrase Bxb1.
Vishnu Hosur
Benjamin E. Low
Michael V. Wiles

Follow this and additional works at: https://mouseion.jax.org/stfb2022
Part of the Life Sciences Commons, and the Medicine and Health Sciences Commons

REVIEW
published: 05 July 2022
doi: 10.3389/fbioe.2022.910151

Programmable RNA-Guided Large
DNA Transgenesis by CRISPR/Cas9
and Site-Speciﬁc Integrase Bxb1
Vishnu Hosur *, Benjamin E. Low and Michael V. Wiles
The Jackson Laboratory for Mammalian Genetics, Bar Harbor, ME, United States

Edited by:
Yajie Wang,
Westlake University, China
Reviewed by:
Hengqian Ren,
University of Illinois at UrbanaChampaign, United States
Xiaofei Song,
Zhejiang University of Technology,
China
Xiong Xiong,
Entry Level Professional, Genscript
(United States) Piscataway, United
States
*Correspondence:
Vishnu Hosur
vishnu.hosur@jax.org

The inability to insert large DNA constructs into the genome efﬁciently and precisely is a key
challenge in genomic engineering. Random transgenesis, which is widely used, lacks
precision, and comes with a slew of drawbacks. Lentiviral and adeno-associated viral
methods are plagued by, respectively, DNA toxicity and a payload capacity of less than
5 kb. Homology-directed repair (HDR) techniques based on CRISPR-Cas9 can be
effective, but only in the 1–5 kb range. In addition, long homology arms—DNA
sequences that permit construct insertion—of lengths ranging from 0.5 to 5 kb are
required by currently known HDR-based techniques. A potential new method that
uses Cas9-guided transposases to insert DNA structures up to 10 kb in length works
well in bacteria, but only in bacteria. Surmounting these roadblocks, a new toolkit has
recently been developed that combines RNA-guided Cas9 and the site-speciﬁc integrase
Bxb1 to integrate DNA constructs ranging in length from 5 to 43 kb into mouse zygotes
with germline transmission and into human cells. This ground-breaking toolkit will give
researchers a valuable resource for developing novel, urgently needed mouse and human
induced pluripotent stem cell (hiPSC) models of cancer and other genetic diseases, as well
as therapeutic gene integration and biopharmaceutical applications, such as the
development of stable cell lines to produce therapeutic protein products.
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Researchers have discovered numerous links or correlations between putative structural variations
(SVs) and gene expression and between SVs and phenotype, via long-read sequencing analysis of
clinical samples and via large-scale collaboration programs such as ENCODE (The ENCODE Project
Consortium, 2012). Some of the most common causes of cancer, including tumor suppressor genes
(TSG) and oncogenic genes (ONC), originate at least in part from huge tandem duplications (TD)
(Menghi et al., 2016; Willis et al., 2017; Menghi et al., 2018), as well as from kilobase-sized clusters of
transcriptional enhancers, known as super-enhancers (SE) (Hnisz et al., 2013; Hnisz et al., 2015;
Dave et al., 2017; Wang et al., 2019; Tang et al., 2020). However, researchers’ ability to study the role
of large SVs in disease via model generation or synthetic biology is hindered by the inability to
efﬁciently integrate large DNA constructions (greater than 10 kb) in mouse zygotes (Wang et al.,
2013; Yang et al., 2013; Wang et al., 2015; Liu et al., 2019), mouse embryonic stem (mES) cells (Wang
et al., 2015; Liu et al., 2019), or human cells (Chu et al., 2015; Jasin and Haber, 2016; Yang et al., 2020).
Studies hindered by this barrier include: 1) generation of particular, potentially powerful mouse
models [e.g., replacing a 100-kb region with its human equivalent requires at least three to 4 years
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(Wallace et al., 2007)], 2) identiﬁcation of novel gene function
when the gene is large, and 3) humanization of large regions of
the mouse genome to study infectious diseases such as SARSCoV-2, Ebola, and Hepatitis C virus. The need for an approach
for insertion of large DNA constructs into the genome is
highlighted by the current lack of an approach for effective
modiﬁcation of genome-wide DNA structures.
To meet the urgent requirement for approaches enabling largeDNA-construct integration, three distinct groups have collaborated
to create a versatile and creative targeted transgenesis toolkit based
on the Cas9-Bxb1 integrase system for accurate insertion of kb-sized
DNA into the mammalian genome. Bxb1 integrase catalyzes
effective and precise transgenesis by using DNA attachment sites
(attP in the host genome and attB in the donor DNA, or attB in the
host genome and attP in the donor DNA) as substrates (see Box 1).
While alternative integrases such as phiC31, A118, SPBc, W, phiBT1,
and phi370.1 are available, Bxb1 is the integrase of choice based on
evidence that Bxb1, unlike these other integrases, has high efﬁciency
and lacks pseudo sites in the mammalian genome. The new Cas9Bxb1 toolkit will be useful for making important mouse models with
large DNA inserts, such as potential new models for the Somatic Cell
Genome Editing Consortium and humanized models of infectious
illnesses, and will also be valuable for cell engineering and
therapeutic gene therapy.

et al., 2018), are highly efﬁcient in the range of 1–6 kb, the
efﬁciency of precise introduction of fragments greater than
~7 kb in length is still not robust. The payload capacity of
lentiviral-based techniques is superior (18 kb) (Chaudhari
et al., 2020), but these techniques are linked to serious side
effects such as genotoxicity (Montini et al., 2006) and
immunogenicity (Nayak and Herzog, 2010). Although AAVs
have few side effects, their payload capacity is less than 5 kb
(Lai et al., 2010).
DNA transposases coupled with catalytically dead Cas9 for
RNA-guided site-speciﬁcity have recently been designed to
perform targeted transgenesis of up to 10 kb of DNA in
bacteria (Munoz-Lopez and Garcia-Perez, 2010; Peters et al.,
2017; Strecker et al., 2019; Vo et al., 2020). However, to date
this system can be used only with prokaryotes. Furthermore, the
signiﬁcant off-target activity of transposases necessitates
extensive engineering to accomplish efﬁcient transgenesis. In
addition, Sleeping Beauty and piggyBac, two of the most
promising DNA transposons, are also linked to severe DNA
toxicity (Wang et al., 2008; Tipanee et al., 2017).
In addition to the limitations discussed above, current approaches
lack several other capabilities critical for efﬁcient, versatile genetic
engineering, including the ability to modify the genome sequentially
to allow integration of additional kb-sized DNA constructs at a preexisting locus (Brosh et al., 2021); control over copy numbers;
control over integration orientation; DNA insertions without long
kilobases of homology arms; and DNA insertions without traces of
extraneous prokaryotic vector DNA. In sum, a key obstacle in
genetic engineering remains the lack of sophisticated and
economical techniques for precise integration of kb-sized DNA in
human cells and animals. To overcome these limitations, a new
toolkit—an RNA-guided Cas9-Bxb1 toolbox (Anzalone et al., 2021;
Grandela et al., 2021; Ioannidi et al., 2021; Low et al., 2021)—has
recently been developed that expands the breadth of precision
transgenesis, genetic engineering, cell-based treatments, and
synthetic biology.

AVAILABLE TOOLS: STRENGTHS AND
WEAKNESSES
Several approaches have been proposed to address some of the
current genetic-engineering gaps, including random transgenesis,
CRISPR/Cas9-mediated HDR, lentiviral-based and adenoassociated viruses (AAVs), and DNA transposases (e.g.,
Sleeping Beauty and piggyBac). However, none of these
approaches address all of the gaps.
Random integration of transgenes is quick but ineffective
(Haruyama et al., 2009; Laboulaye et al., 2018; Goodwin et al.,
2019). It is also plagued by inherent variability as a result of
complicated integrations at multiple locations, which can lead to
segregation, position effects, and, in some cases, disruption of
endogenous coding sequences, all of which complicate and hinder
strain characterization. Furthermore, undocumented cassettes or
even contaminated DNA pieces might be found in random
insertion. Together, these haphazard insertions and
modiﬁcations can result in phenotypic changes unrelated to
function of the transgene.
While CRISPR/Cas9-mediated HDR of kb-sized DNA has
been used to create transgenic mice and cell lines, this approach is
unreliable. It has a variable and low success rate, especially when
large (>10 kb) donor structures are required. Furthermore, while
recent CRISPR/Cas9-based approaches, such as Easi (Efﬁcient
additions with ssDNA inserts)-CRISPR (using long singlestranded DNA donors) (Quadros et al., 2017), SPRINT
(SHERLOCK-based proﬁling of in vitro transcription)-CRISPR
(S-phase pronuclear injection of large DNA) (Abe et al., 2020),
and 2C-HR (two-cell homologous recombination)-CRISPR
(knock-in of large transgenes in two-cell stage embryos) (Gu
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CRISPR/CAS9-ENDONUCLEASE WITH
THE SITE-SPECIFIC INTEGRASE BXB1 IN
MOUSE ZYGOTES
We recently developed an approach using the Bxb1 integrase to
induce precise and efﬁcient integration of large DNA constructs
into the mouse genome (Low et al., 2021). Bxb1 uses attP and attB
attachment sites to accomplish this DNA insertion. In a key
innovative component of developing our approach, we prepositioned an attP attachment site in the ROSA26 safe harbor
locus of several mouse strains, using CRISPR/Cas9-mediated
HDR. We were then able to efﬁciently integrate large DNA
constructs (~5–~43 kb) and generate single-copy transgenic
mice. Below we describe two different versions of this recently
developed approach for integrating large DNA constructs into a
mouse safe harbor locus—version 1, or RMKI (recombinase
mediated knock-in) (Figure 1A), for DNA constructs of up to
10 kb; and version 2, or recombinase-mediated cassette exchange
(RMCE) (Figure 1B), for DNA constructs of up to ~43 kb.
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FIGURE 1 | Version 1 (RMKI): (A) Over the past 5 years, we have generated mice using version 1 [the ﬁrst-generation Cas9-Bxb1.v1 toolbox (a single attPGT site and a single
attBGT site)] with successful targeted transgenesis of a series of DNA constructs up to 9.9 kb in length. The approach involves a) introduction of a single attPGT site into the safe
harbor ROSA26 locus using electroporation in mouse zygotes by CRISPR/Cas9-mediated HDR (A), and veriﬁcation of insertion by PCR and Sanger sequencing, b) from those
zygotes, establishment of a sequence-conﬁrmed attPGT mouse strain—B6-Bxb1.v1 mice, c) pronuclear microinjection of Bxb1 mRNA plus a large DNA construct (up to
9.9 kb) containing a single cognate attBGT site and the desired transgene into zygotes from matings of B6-Bxb1.v1 mice, for Bxb1 integrase-mediated insertion of DNA into the
pre-placed attPGT site for creation of transgenic mice, and d) conﬁrmation of the correct DNA insertion—recombinant attachment left (attL) and right (attR) sites—by PCR, Sanger
sequencing, and Nanopore long-read sequencing, and subsequent appropriate expression of the transgene (top panel). Notably, because the genetic background of mice plays
an important role in improving mouse-to-human translation (Rivera and Tessarollo, 2008; Reilly, 2016; Krupke et al., 2017), examining phenotypes in different genetic backgrounds
can be a useful way to identify modiﬁer genes and novel pathways. Towards this end, we have generated version 1 mice on different genetic backgrounds (bottom panel). Having
the landing pad in more than one inbred mouse strain provides additional capabilities to study complex diseases, including cancer and neurodegenerative diseases. (B) Version 2
(RMCE): Building on the success of version 1 [the ﬁrst-generation (Bxb1.v1) approach], we generated a Bxb1 version 2 (Cas9-Bxb1.v2) toolbox to further improve efﬁciency, and to
enable insertion of even larger DNA constructs. The use of the dual heterologous attachment sites in the genome (attPGA and attPGT), together with dual heterologous sites in the
donor DNA (attBGA and attBGT), enables exclusion of the vector backbone and allows insertion of longer tracts of DNA, as the attBGA and attBGT sites can be placed into any vector,
including bacterial artiﬁcial chromosomes (BACs), simply by ﬂanking the desired region to be integrated. This approach, commonly known as the recombinase-mediated cassette
exchange (RMCE) approach, involves two crossover events between two heterologous or incompatible recombination sites ﬂanking the donor DNA. This method can be used to
exchange large transgene cassettes between the donor DNA and the genome. In Low et al., we provide evidence for insertion of a ~43-kb construct (a threefold increase in size
compared with Bxb1.v1) in B6-Bxb1.v2 mice (top panel). We have successfully generated version 2 mice on two different genetic backgrounds (bottom panel).

ONE-STEP APPROACH (ONE-CELL STAGE,
ELECTROPORATION AND TWO-CELL
STAGE, MICROINJECTION) FOR RAPID
TARGETED TRANSGENESIS OF LARGE
DNA CONSTRUCTS

that attP site, the mice must be backcrossed and then intercrossed to
generate homozygous attP mice (9–12 months). Embryos from the
homozygous attP mice are then microinjected with a large donor DNA
construct containing the transgene and a cognate attB site, followed by
backcrosses and intercrosses to generate homozygous transgenic mice
(another 9–12 months). Our new approach, summarized below,
eliminates these protracted steps by accomplishing both insertion of
the attP site and microinjection of the DNA construct in the same
embryo, thereby eliminating the generation of attP homozygous mice
that is required in existing approaches and creating transgenic mice in
one generation (9–12 months) instead of 18–24 months.

Conventional transgenesis approaches require 18–24 months for
generation of transgenic mice using the Bxb1 integrase; the ﬁrst step
involves insertion of an attP site in the mouse genome using CRISPR/
Cas9-mediated HDR. After characterizing founder animals carrying

Frontiers in Bioengineering and Biotechnology | www.frontiersin.org

3

July 2022 | Volume 10 | Article 910151

Hosur et al.

Cas9+Bxb1 Toolbox

FIGURE 2 | Bxb1-mediated targeted transgenesis of mouse zygotes in one-step. (A) At the zygote one-cell stage, using Cas9-mediated HDR, we inserted an
attPGA site in the Cd68 locus, adjacent to the start codon (ATG). (B) At the two-cell stage, in the same embryos, using Bxb1 we inserted a Cas9-EGFP reporter gene
containing a cognate attBGA site. (C) The alleles with correct integration were used for germline transmission.

In the ﬁrst step of our new approach, CRISPR/Cas9-meditated HDR
in mouse zygotes via electroporation is used to insert, at the one-cell
zygote stage, an attP site immediately downstream of the transcription
initiation site ATG (Figure 2A). Then, in step 2, using the same
embryos but at the two-cell stage, microinjection is used to introduce, in
the presence of Bxb1 mRNA, large donor DNA constructs carrying the
transgene and the cognate attB site, allowing efﬁcient, precise
recombination of the donor DNA into the genomic attP site in a
single generation (Figures 2B,C). Notably, electroporation is
advantageous for both embryo survival and efﬁciency of HDRmediated insertion of short oligos, whereas microinjection at the
two-cell stage is essential for delivery of large DNA payloads. This
novel one-step approach [one-cell stage, Electroporation (EP); and twocell stage, Microinjection (MIJ)] not only signiﬁcantly reduces the
generation time, it, more importantly, enables a “plug-and-play”
approach, i.e., one-step insertion of a large DNA construct in
multiple mouse strains with no pre-placed attachment sites.
We used this innovative approach to successfully generate
Cd68-cas9 transgenic mice in one generation on the NSG
background with 13% Bxb1-mediated integration efﬁciency.
We sequence-conﬁrmed that the cas9 transgene was correctly
integrated into the mouse Cd68 endogenous locus. Homozygous
mice are viable with no gross abnormalities.

sequencing) from DNA isolated from tail tissues, and Oxford
Nanopore Technology’s Cas9-mediated ampliﬁcation-free
enrichment approach (Gilpatrick et al., 2020), a targeted
sequencing approach. The Nanopore approach is relatively
low-cost and can be applied to various starting materials, all
while enriching regions of interest over native sequences.
Importantly, neither of our two validation approaches
requires sacriﬁcing animals. Brieﬂy, our workﬂow for the
Nanopore targeted sequencing involves: 1) high molecular
weight genomic DNA is extracted from mice carrying the
transgene by using tissue from ear notches, 2) the region of
interest is targeted by the Cas9-single guide RNA (sgRNA)
complex and excised from the gDNA, 3) the resulting
fragment is used to construct a Nanopore sequencing
library without the need for ampliﬁcation, and 4) upon
sequencing, the region of interest is greatly enriched
compared to the background gDNA (Figure 3). We have
already validated the Nanopore targeted sequencing
approach for transgenic inserts ranging from 5 to 43 kb in
length (Low et al., 2021). Moreover, we enabled validation of
not only the inserted transgene but also the regions bordering
the two ends of the Bxb1 integration site (attPGT and attPGA)
in the ROSA26 locus, by designing sgRNAs 2 kb upstream and
downstream of the integration site.

TARGETED NANOPORE LONG-READ
SEQUENCING FOR EFFICIENT
VALIDATION OF CORRECT INSERTION OF
TRANSGENIC LOCI

TWIN PRIME EDITING + BXB1
Twin Prime Editing (TwinPE) + Bxb1 enables targeted
integration of large DNA plasmids (~5.6 kb) at various
safe-harbor loci in human cells (Anzalone et al., 2021)
(see Box 2). Simultaneous delivery of a twinPE + Bxb1
complex with large donor plasmids enables integration at

To ensure conﬁrmation of correct insertion of transgenes, we
have used two approaches: classical genotyping (PCR, Sanger
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FIGURE 3 | Designing a Cas9 targeted assay: Dual cut designs use a 5′ and 3′ sgRNA ﬂanking the region of interest. The resulting library leads to generation of high
coverage over the desired region (e.g., 5–30 kb), ideal for transgene validation. We have successfully used mouse ear notches to generate sufﬁcient high molecular
weight genomic DNA to sequence a 30-kb region up to 44x.

PROGRAMMABLE ADDITION THROUGH
SITE-SPECIFIC TARGETING ELEMENTS

multiple genomic loci, permitting multiplexing capabilities.
Notably, twinPE + Bxb1 mediates precise donor integration
at the targeted site without causing inappropriate donor
integration into the human genome (Figure 4A).
Furthermore, because the modeling of large structural
variants, including DNA inversions and rearrangements,
involved in cancer and other diseases can be challenging,
Anzalone et al. demonstrate that TwinPE + Bxb1 can
facilitate inversions in human cells. The authors examined
a ~40-kb inversion between IDS and its pseudogene IDS2 to
test the twinPE-Bxb1 inversion method on a therapeutically
relevant locus. Inversions between these locations have been
found in 13% of Hunter syndrome patients, and
identiﬁcation of the breakpoints in pathogenic alleles has
showed that the inversion frequently occurs inside a
recombination hotspot seen in both IDS and IDS2.
Flanking the recombination hotspots with attB and attP
sequences, the authors demonstrate unidirectional
inversion by Bxb1 resulting in attL and attR sites,
suggesting successful repair of the pathogenic allele.
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Programmable Addition through Site-speciﬁc Targeting
Elements (PASTE), developed by Ioannidi et al. (2021), is
simply Bxb1 fused to the PE2 prime editor protein
(Figure 4B). PASTE achieves integration of DNA segments
ranging in size from 779 bp to ~36 kb at efﬁciencies up to ~55%
in multiple cell types, including both dividing and nondividing cells (Ioannidi et al., 2021). The authors observed
no off-target activity with PASTE. The range of segment sizes
that can be efﬁciently inserted would enable insertion of more
than 99.7% of human cDNAs, illustrating the research
potential of the approach. The construct used in PASTE
includes a Cas9 protein fused to a reverse transcriptase, a
pegRNA, and a large serine integrase Bxb1. Importantly, in a
novel step, the construct also incorporates the key elements
used for efﬁcient DNA insertion via serine integrases, which
typically insert sequences containing an attP attachment site
into a target containing the related attB attachment site, or
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FIGURE 4 | (A) TwinPE + Bxb1-mediated insertion of an attP sequence and creation of a landing pad in human cells for efﬁcient insertion of large DNA sequences in
the safe harbor locus. Whereas the previously described PE2 system uses a Cas9 nickase, an engineered MMLV-RT enzyme, and a pegRNA, the TwinPE uses two PE2
complexes that target two protospacer sequences on opposite strands. The TwinPE + Bxb1 system can make the pegRNA-encoded template with the desired insertion
of short sequences (e.g., attP or attB) and replace the original DNA sequence. (B) PASTE is simply the PE2 system [a Cas9 nickase, an engineered MMLV-RT
enzyme, and an attachment site-containing guide RNA (atgRNA) or pegRNA] fused with the Bxb1-integrase.

“landing site.” While existing attP/attB insertion approaches
use a two-step method for DNA insertion, i.e., integration of
the attP site and associated donor DNA into an attB landing
site previously incorporated into the genome, the PASTE
construct includes both the attP site and the attB site, the
latter of which is incorporated into the pegRNA design and is
copied into the genome via reverse transcription and ﬂap
repair. Because the construct includes both 1) a circular
double-strand DNA template containing the donor DNA
and the attP site, and 2) the attB landing site incorporated
within the pegRNA design (collectively termed the
“attachment site-containing guide RNA; atgRNA”), the
DNA cargo can be integrated at the target site in a single
reaction. Speciﬁcally, the attB landing site is inserted via a
Cas9-directed reverse transcriptase, followed by attPmediated landing site recognition, and integration of the
DNA cargo via a Cas9-directed integrase.
The authors demonstrated the power and versatility of PASTE
by showing that PASTE can be used for: 1) the tagging of genes,
i.e., genes were tagged with GFP using PASTE, and results showed
that GFP co-localized with the tagged gene product as expected;
2) multiplexed gene integration, i.e., the authors simultaneously

Frontiers in Bioengineering and Biotechnology | www.frontiersin.org

integrated three different genes at three genomic loci; 3) direct
insertion of DNA templates carried by AAV or adenoviral
vectors; and 4) integration of therapeutic genes with
subsequent expression of therapeutic protein products. For
example, alpha-1 antitrypsin (encoded by SERPINA1) and
carbamoyl phosphate synthetase I (encoded by CPS1) are
involved in human Alpha-1 antitrypsin deﬁciency and CPS1
deﬁciency, respectively. To test protein production of these
two proteins, Ioannidi et al. (2021) used PASTE to deliver
SERPINA1 or CPS1 cargo and found effective integration at
the ACTB locus in human cells. Furthermore, the authors
provided evidence for protein expression, intracellular
accumulation of the transgenic products, and secretion of
proteins into the medium. Lastly, the authors also took steps
to optimize PASTE by using metagenomic mining to discover
thousands of putative integrase and attachment site
combinations, and to engineer multiple novel integrase
orthologs with improved activity and reduced attachment-site
requirements. Importantly, a different study used PASTE with
human cells to achieve precise integration of templates as large as
~36 kb with ~10%–20% integration efﬁciency (Ioannidi et al.,
2021).
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FIGURE 5 | Design and implementation of large DNA transgenesis in mouse ESCs and human iPSCs: (A) The ICE (adapted from Iacovino, Bosnakovski, Fey et al.)
(Iacovino et al., 2011) tool uses a landing pad site in the safe harbor locus, which contains the cre recombinase gene driven by the tetracycline-responsive promoter (TRE)
and an inactive neomycin resistance gene (NeoR) lacking a promoter, a consensus Kozak sequence, and a translation initiation codon (ATG). Notably, only the cre gene is
ﬂanked by two heterologous loxP/loxP* sites. Following insertion of the landing pad, large donor DNA ﬂanked by two heterologous loxP*/loxP sites, in the opposite
orientation, is integrated into the landing pad via doxycycline/tetracycline-induced expression of cre-recombinase. Cre is then replaced by the large DNA, which allows
the neomycin resistance gene to be turned on for positive selection of ES cells that have been correctly integrated. (B) Big-IN (adapted from Brosh et al.,2021) is also a
cre-mediated RMCE-based technique for replacing large sections of mammalian genomes. Using CRISPR/Cas9-mediated HDR, a landing pad site is inserted into a safe
harbor locus in mouse ES cells (or human cells) to efﬁciently engineer mouse and human cells. Insertion of large DNA containing a promoter to drive puromycin, inducible
cre, and an HSV1-TK gene, ﬂanked by heterologous loxP and loxP mutant (loxP*) sites, enables cre-mediated recombination of two pairs of heterologous loxP and loxP*
sites, resulting in large DNA cassette exchange. While puromycin allows for selection and isolation of a landing pad containing ES cells, correctly integrated ES cell lines
can be counter-selected by ganciclovir. Modiﬁed ES cells can be taken to germline transmission. (C) The Straight-IN (adapted from Grandela et al., 2021) tool uses a
combination of Bxb1 (or phiC31)- and cre-mediated recombination to insert a safe harbor locus in human iPSCs for large DNA transgenesis. Similarly to the ICE
approach, Straight-IN uses a heterologous loxP and loxP* site-ﬂoxed landing pad cassette containing an attP site, an inactive antibiotic resistance gene (*BsdR), and a
ﬂuorescent reporter gene driven by a constitutive promoter such as pgk1. The donor vector consists of a cognate attB site, a constitutive promoter preceding a
translation initiation codon (ATG), and the DNA payload ﬂoxed by heterologous loxP and loxP* sites. Successful Bxb1-mediated integration of large DNA results in the
formation of attR and attL recombination sites and activation of the antibiotic gene for positive selection of clones. Finally, the double loxP and loxP* sites make it possible
to remove the selection markers, which are the ﬂuorescent reporter and the antibiotic gene.

ASSEMBLY AND DELIVERY OF 100’S OF KB
OF DNA

strategy that surmounts two major challenges in synthetic
genomics: the assembly and delivery of long DNA sequences.
Speciﬁcally, the investigators developed a workﬂow termed
“eSwAP-IN” (extrachromosomal Switching Auxotrophies
Progressively by Integration) that enables de novo assembly of
DNA sequences of interest in yeast; leveraged a previously
described gene-trap-based system termed “ICE” (Inducible
Cassette Exchange) to deliver large, assembled DNA constructs
to mouse embryonic stem cells (mESCs) (Figure 5A); and tested

Synthetic genomics—the design and synthesis of genomes, or key
regions of them—is an emerging ﬁeld in the study of genome
function and biological processes. While synthetic genomics has
been applied to investigation of viral and microbial genomes,
further advances are required to apply this approach to the study
of larger mammalian genomes. Mitchell et al. (2021) developed a
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BOX 1 | Site-speciﬁc serine recombinases
Site-speciﬁc recombinases are enzymes that cut and rejoin DNA strands at precise genomic locations. Large serine and tyrosine integrases are two classes of
bacteriophage recombinases with a nucleophilic active site amino acid residue (serine and tyrosine, respectively) that breaks DNA sequences by targeting DNA
phosphodiester linkages (Grindley et al., 2006). Although the functions of tyrosine and serine integrases are similar, their mechanisms of action are very different.
Tyrosine recombinases (e.g., Cre and Flp) mediate bidirectional DNA integration into the bacterial genome. In contrast, serine recombinases mediate DNA integration
into the bacterial genome by catalyzing unidirectional, i.e., recombination, between two attachment sites, attP (Phage) and attB (Bacterium), resulting in the production
of recombinant attachment left (attL) and right (attR) sites (Stark, 2017). Furthermore, compared to tyrosine recombinase attachment sites, the attachment sites of
serine recombinases are quite small—50 bp for attP and 40 bp for attB. Each of these att sites (attP and attB) binds an integrase dimer, and recombination takes place
in a complex containing an integrase tetramer that holds two att sites (attL and attR) together. Notably, in conjunction with a serine recombinase, the phage-encoded
protein recombination directionality factor (RDF) is required for initiating the reverse reaction, i.e., recombination between recombinant attL and attR sites in the opposite
direction. Because serine recombinases facilitate precise DNA integration, excision, inversion, and translocation, they have been used in a range of
applications—molecular genetics, gene therapy, biotechnology, and synthetic biology (Merrick et al., 2018), (Yan et al., 2013).

for payload integration and expression of the integrated gene via
PCR and immunoblot, respectively. The eSwAP-IN workﬂow
harnesses the inherent capacity of the yeast Saccharomyces
cerevisiae to perform homologous recombination; S. cerevisiae
can stitch multiple DNA sequences together with high ﬁdelity,
given a minimum of 40 bp of terminal sequence homology
encoded by adjacent parts. The eSwAP-IN workﬂow is a
modiﬁcation of the previously described SwAP-IN method.
For “in yeasto” DNA assembly, both eSwAP-IN and SwAP-IN
incorporate, in a step-wise fashion, DNA segments into a
progressively longer construct termed an assemblon. The
major modiﬁcation in eSwAP-IN relative to SwAP-IN is that
the assemblon is assembled extrachromosomally in a circular
format, and thus replicates and segregates independently of the
native yeast chromosomes. Another important advantage of the
circular format is that the assemblon can theoretically be directly
transferred into E. coli for preparation of large quantities of
puriﬁed DNA for delivery to the organism of choice.
Accordingly, the vector used for insertion of the DNA
assemblon in the organism of choice encodes features to
support replication, segregation, and selection in both yeast
and E. coli.
To demonstrate the capacity of eSwAP-IN for efﬁcient
assembly of large DNA segments, the investigators assembled
the 101-kb human HPRT1 (hHPRT1) gene and then delivered the
assemblon to mESCs using the ICE system. This system employs
an mESC line with a landing pad on the X chromosome that
includes a doxycycline-inducible CRE transgene. Induction of
Cre expression renders the cells recombination-competent, and
delivery of an appropriately designed DNA construct results in
cassette exchange recombination and replacement of CRE with
the incoming DNA. The investigators demonstrated the use of
ICE for successful delivery of a 114-kb construct to mESCs and
precise integration of the custom-built 101-kb hHPRT1 locus into
the ICE landing pad.
Although the ICE approach enables delivery of ~100-kb DNA
payloads, it leaves scars ﬂanking the integrated DNA in the
mammalian genome. Recently, Brosh et al. (2021) developed
an alternative platform, termed Big-IN, for efﬁcient, repeated
targeted integration of large DNA segments into mammalian
cells, and a scalable pipeline for validation of the engineered cells.
They demonstrated use of Big-IN for integration of DNA up to
143 kb in length in human embryonic stem cells (hESCs) and
mouse ESCs (Figure 5B).
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In brief, a short landing pad is targeted to replace a genomic
locus of interest using CRISPR/Cas9-mediated HDR, followed by
single-step payload integration via Cre recombinase-mediated
cassette exchange (RMCE). To accomplish this, cells are
transfected with two plasmids: 1) a pCas9 plasmid expressing
guide RNAs (gRNAs) targeting the region of interest, and 2) a
short landing pad that includes a promotor driving expression of
a puromycin-resistance gene, a thymidine kinase gene, and a Cre
gene; a mutant lox site (lox 2272) and a loxP site, to permit Cremediated RMCE; and, ﬂanking the two lox sites, homology arms
(HA) corresponding to the genomic sequences that ﬂank the
gRNA target sites at the targeted genomic locus. Fixed insertion of
the transiently transfected plasmid is accomplished by inducing
its linearization via cloning of the same gRNA target sequences
and protospacer adjacent motifs into the vector backbone just
outside the HAs. Insertion is validated using PCR genotyping
with primers targeting the novel junctions between the landing
pad and the genomic sequences beyond the HAs; Sanger
sequencing for base-pair resolution of correct landing pad
integration; and quantitative real-time PCR for loss of targetgene expression and gain of Cre expression. The investigators also
developed a modular next-generation sequencing pipeline,
including use of hybridization capture sequencing, for
validation of loss of the target locus, gain of the landing pad,
and absence of the vector backbone and pCas9.
Big-IN is an advance over previous genetic-engineering
approaches in that it facilitates one-step scarless delivery of
large DNA payloads. Furthermore, the capacity of Big-IN for
single-step construct integration enables repeated deliveries to the
same allele, thereby minimizing technical factors that can hinder
efﬁcient integration, and thus is ideal for comprehensive
examination of a given locus. In addition, the approach is
designed to be scalable across multiple loci and cell lines, with
delivery and selection methods that can be employed in a
modular fashion to address problems associated with speciﬁc
loci and cell types. Further, the validation strategy is designed to
enable early validation of construct integration.
Grandela et al. (2021) recently presented STRAIGHT-IN
(Serine and Tyrosine Recombinase Assisted Integration of
Genes for High-Throughput INvestigation), a novel approach
for integrating large DNA payloads into hiPSCs that combines
the beneﬁts of both serine (Bxb1) and tyrosine recombinases (cre
or Flp) (Figure 5C). The authors ﬁrst generated hiPSCs with a
landing pad cassette containing attachment sites (attP) for Bxb1
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BOX 2 | Prime Editing (PE) and Twin Prime Editing (TwinPE)
Most existing technologies, including those using the CRISPR-Cas9 system, leverage induction of double-strand breaks (DSBs), a process that, as a result of genome
damage, results in undesirable outcomes. More recent technologies, including base editing (Komor et al., 2016) and prime editing (Anzalone et al., 2019), circumvent
the need for DSBs, but are associated with signiﬁcant drawbacks. Base editing involves exchanging one nucleotide for another but can be used to make only a
small number of nucleotide changes. Prime editing involves cutting only one strand of DNA, followed by the use of reverse transcriptase to “prime,” or initiate, the transfer
of new genetic information encoded in an engineered guide RNA termed “prime editing guide RNA; pegRNA,” followed by reconstruction of the other DNA strand so
that it corresponds to the new genetic material. While PE has been shown to have the capacity for efﬁcient genome modiﬁcation, it can generate only small insertions
(<~50 bp).
To enable insertion of DNA sequences larger than ~50 bp, Anzalone et al. (2021) recently developed a novel twin prime editing (twinPE) strategy. This method uses
two pegRNAs—one nicks one of the two DNA target strands, and the other nicks the other strand, with each pegRNA directing the synthesis of a 3′ ﬂap complementary
to the 3′ ﬂap produced by the other pegRNA. The 3′ ﬂaps hybridize with each other to form an intermediate strand with annealed 3′ overhangs of the new DNA sequence
and annealed 5′ overhangs of the original DNA sequence. After the original DNA sequence is excised, the gap is ﬁlled by the reverse transcriptase enzyme, and a nick site
ligation is performed between the two nicks, with a 3′ ﬂap sequence replacing the endogenous sequence between the nicks. The edit results in the introduction of a new
DNA sequence, either by deleting a portion or modifying a portion of the original DNA sequence. In human cells, twinPE has been shown to successfully generate larger
insertions (~100 bp) than can be generated with the PE strategy. Nevertheless, twinPE falls short of integrating large kilobase-sizes DNA fragments into the genome.

at the safe harbor locus AAVS1 using CRISPR/Cas9-mediated
HDR. Next, using a series of donor DNA constructs ranging in
size from 2 to 50 kb with cognate attachment sites (attB), the
authors examined Bxb1-mediated recombination in hiPSClanding pad cells and observed efﬁcient (up to 50% with
antibiotic selection) integration of donor DNA independent of
size restraints. Additionally, to examine the upper limit of DNA
payload integration, the authors tested integration of a large 170kb BAC construct with cognate attB sites and observed successful
site-speciﬁc integration of the large construct into the landing pad
site as examined via PCR ampliﬁcation across attR and attL sites,
and via digital droplet PCR (ddPCR) to determine the copy
number of the integrated DNA. Notably, the landing pad
attachment site (attP) is ﬂanked by heterologous loxP/loxP*
sites, which enables cre-mediated excision of the vector
backbone components avoiding any vector-related adverse
effects. Together, these ﬁndings suggest that the Cas9-Bxb1
toolkit can help with the precise integration of large DNA
payloads into hiPSCs as well.
While the aforementioned recombinase-based approaches can
theoretically be applied to any gene locus of any length, success
depends on the ability to source the required DNA, by PCR or
commercial synthesis; the degree to which yeast tolerates the
sequence composition of the lengthening assemblon; and the
upper limit for chromosome stability in yeast. Mitchell et al.
expect that the upper length limit of bacterial or mammalian
constructs assembled and maintained in yeast is well over 1 Mb,
and that a set of particular technical advances including
laboratory automation may facilitate realization of large-scale
genome writing in mammalian cells.

studies can explore the capacity for integration of DNA
constructs up to 100 kb in length and further test a “plug-andplay” approach for rapid generation of transgenic mice.
Because serine integrase-based recombination systems
exhibit high speciﬁcity of for site-directed unidirectional
recombination and high orthogonality to the mammalian
genome, with no signiﬁcant off-target activity, these systems
have recently received widespread interest. From prophage
genomes, using bioinformatics tools, Yang et al. uncovered
34 phage integrases and their predicted attB and attP
recognition sites with no detectible off-target activity.
Recently, Durrant et al. developed a systematic
computational method for identifying thousands of novel
serine integrases and their cognate attachment sites for
insertion of large DNA segments. This technique has resulted
in identiﬁcation of three types of serine integrases: 1) integrases
that can insert DNA into pre-positioned attachment sites (e.g.,
Pa01, Si74, and Nm60 integrases showed enhanced
recombination of attP-donor plasmid DNA into attB
landing-pad cells with minimal off-target activity compared
with either Bxb1 or PhiC31); 2) integrases that can insert
DNA into predicted pseudosites (e.g., Sp56, Pf80, and Enc3
can target the human genome at predicted target sites without
pre-placed attachment sites); and 3) multi-targeting integrases
that can insert DNA into multiple sites simultaneously (e.g.,
Cp36 integrated DNA into multiple loci with greater than 40%
efﬁciencies in HEK293FT and K562 human cell lines with no
pre-positioned landing-pad sites). Furthermore, experimental
analyses of these integrases in human cells suggested sevenfold
higher integration efﬁciencies than Bxb1, and genome insertion
efﬁciencies of 40%–70% with DNA insert sizes of 7 kb. Notably,
since the computational analyses identiﬁed both the integrases
and the target sites, this would enable identiﬁcation of offtargets in the human genome for effective genome therapy.
It will be exciting to apply this technology in cancer
genomics, human genetics, systems biology, and cellular
engineering to integrate large DNA constructs to model
human diseases. Lastly, because the approaches extend
beyond the integration of large kb-sized DNA segments to
the generation of DNA inversions, it will be interesting to
study the efﬁciency of Bxb1 integrase in generating DNA
rearrangements and achieving conditional mutagenesis. In

CONCLUSION AND FUTURE DIRECTIONS
Targeted serine-integrase-based genome insertion is a key
component of biomedical research and therapy development.
However, until recently, previous approaches lacked the capacity
for efﬁcient insertion of large (>5 kb) DNA segments. Recent
studies have developed, implemented, and validated multiple
versions of a revolutionized Cas9-Bxb1-targeted integrase
system to enable diverse novel genetic-engineering approaches
based on efﬁcient insertion of large DNA constructs. Future
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sum, this novel exciting technology, which has been validated
both in vitro and in vivo, has signiﬁcant clinical implications
for treating various human genetic disorders as well as
generating and studying next-generation mouse models of
human disease. comment.
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